Along this line, CTLA4-Ig treatment was found to significantly reduce T-cell repertoire restriction [24] and to significantly increase peripheral blood-derived CD4posCD25posFoxP3pos regulatory T lymphocyte rate in RA patients together with their apoptosis [25]. Here, CTLA4 is linked to rheumatoid arthritis.